Filtros de búsqueda

Lista de obras de Chris Twelves

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

artículo científico publicado en 2015

'Tablet burden' in patients with metastatic breast cancer

artículo científico publicado en 2015

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma ⬇️

scientific article published on 25 May 2016

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

artículo científico publicado en 2004

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors ⬇️

artículo científico publicado el 15 de marzo de 2011

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials

artículo científico publicado en 2015

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours

artículo científico publicado en 2007

A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

artículo científico publicado en 2015

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

artículo científico publicado en 2019

A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors

artículo científico publicado en 2004

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

artículo científico publicado en 2003

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer

artículo científico publicado en 2003

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer

artículo científico publicado en 1994

A qualitative investigation of the motivations, experiences and views of female sunbed users under the age of 18 in England

artículo científico publicado en 2013

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer

artículo científico publicado en 2005

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer

artículo científico publicado en 2014

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

scientific article published on 10 May 2019

Acute reversible neurological deficit following intrathecal chemotherapy

artículo científico publicado en 1991

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

artículo científico publicado en 2012

Answering patients' needs: oral alternatives to intravenous therapy

artículo científico publicado en 2001

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

artículo científico publicado en 2014

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

scientific article published on 01 January 1999

Breast cancer and liver metastases--incidence, diagnosis and outcome ⬇️

artículo científico publicado el 1 de agosto de 1992

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

artículo científico publicado en 2020

Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?

artículo científico publicado en 2002

Capecitabine (Xeloda): from the laboratory to the patient's home

artículo científico publicado en 2002

Capecitabine as adjuvant treatment for stage III colon cancer

artículo científico publicado en 2005

Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience

artículo científico publicado en 2002

Capecitabine plus docetaxel combination therapy

artículo científico publicado en 2005

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy ⬇️

artículo científico publicado el 6 de septiembre de 2011

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

scientific article published on 01 March 2000

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study

artículo científico publicado en 2005

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.

artículo científico publicado en 2018

Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling ⬇️

artículo científico publicado en 2016

Chemotherapy of advanced breast cancer: outcome and prognostic factors

artículo científico publicado en 1993

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer

artículo científico publicado en 2012

Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery

artículo científico publicado en 2009

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests

artículo científico publicado en 1992

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

artículo científico publicado en 2002

Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE study group

Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer

artículo científico publicado en 2014

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database

artículo científico publicado en 2013

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial

artículo científico publicado en 2004

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer ⬇️

artículo científico publicado en 2016

Defining the optimal schedule of drug administration: art or science?

artículo científico publicado en 2008

Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro ⬇️

artículo científico publicado en 2016

Designing phase II trials in cancer: a systematic review and guidance ⬇️

artículo científico publicado el 28 de junio de 2011

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

artículo científico publicado en 2006

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database

artículo científico publicado en 2016

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

artículo científico publicado en 2004

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer

artículo científico publicado en 2016

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

artículo científico publicado en 1992

Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests

artículo científico publicado en 1998

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co

artículo científico publicado en 2014

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer

artículo científico publicado en 2014

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

artículo científico publicado en 1998

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites

artículo científico publicado en 1999

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

artículo científico publicado en 2002

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients

artículo científico publicado en 2011

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

scientific article published on 08 July 2020

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

artículo científico publicado en 2014

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

artículo científico publicado en 2006

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme

artículo científico publicado en 2003

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

artículo científico publicado en 2014

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

artículo científico publicado en 2011

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study

artículo científico publicado en 2008

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

artículo científico publicado en 2015

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

artículo científico publicado en 2015

Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer

artículo científico

First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer

artículo científico publicado en 2014

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

artículo científico publicado en 2002

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

artículo científico publicado en 2011

Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation

artículo científico publicado en 1989

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial ⬇️

artículo científico publicado en 2015

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

artículo científico publicado en 2017

Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study

artículo científico publicado en 2008

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

artículo científico publicado en 2011

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database

artículo científico publicado en 2013

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

scientific article published on 29 November 2019

In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer ⬇️

artículo científico publicado el 3 de junio de 2011

Individualizing treatment to optimize survival outcomes in breast cancer

artículo científico publicado en 2013

Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis ⬇️

artículo científico publicado en 2013

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. ⬇️

artículo científico publicado en 2018

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

artículo científico publicado en 2013

Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma

artículo científico publicado en 2009

Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer

artículo científico publicado en 2013

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer ⬇️

artículo científico publicado el 6 de octubre de 2003

Moving forward with capecitabine: a glimpse of the future

artículo científico publicado en 2002

New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois.

artículo científico publicado en 2011

Novel treatment options in the management of metastatic breast cancer.

scientific article published on May 2011

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer

artículo científico publicado en 2017

Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).

artículo científico publicado en 2004

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

artículo científico publicado en 2003

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

artículo científico publicado en 2001

Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).

artículo científico publicado en 2002

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

artículo científico publicado en 2006

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

scholarly article by Whitney P Kirschbrown et al published June 2019 in Cancer Chemotherapy and Pharmacology

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors

artículo científico publicado en 2007

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

artículo científico publicado en 1998

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors

artículo científico publicado en 2003

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study

artículo científico publicado en 2005

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors

artículo científico publicado en 2005

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

artículo científico publicado en 2012

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group

artículo científico publicado en 2004

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer

artículo científico publicado en 2006

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

artículo científico publicado en 2009

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

artículo científico publicado en 2002

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

scientific article published on 02 August 2010

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane ⬇️

artículo científico publicado en 2015

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

artículo científico publicado en 2010

Phosphorus-31 metabolism of human breast--an in vivo magnetic resonance spectroscopic study at 1.5 Tesla

artículo científico publicado en 1994

Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy

artículo científico publicado en 1994

Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor

artículo científico publicado en 2013

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

artículo científico publicado en 2007

Potential regional differences for the tolerability profiles of fluoropyrimidines

artículo científico publicado en 2008

Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance

scientific article published on 05 July 2019

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also

artículo científico publicado en 2015

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

artículo científico

Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy ⬇️

artículo científico

Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial

Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial

artículo científico publicado en 2013

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Quality of life in clinical trials of metastatic breast cancer.

artículo científico publicado en 2014

Quality of life in women with advanced breast cancer treated with docetaxel

artículo científico publicado en 2004

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization f

article

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients

artículo científico publicado en 2009

Recognizing the place of trials with treatment of physician's choice as the control arm.

artículo científico publicado en 2015

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms

artículo científico publicado en 2020

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

artículo científico publicado en 2020

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial ⬇️

artículo científico publicado en 2016

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

scientific article published on May 2009

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database

artículo científico publicado en 2020

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer ⬇️

artículo científico publicado en 2016

Sunbed use in children aged 11-17 in England: face to face quota sampling surveys in the National Prevalence Study and Six Cities Study

artículo científico publicado en 2010

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

artículo científico publicado en 2002

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

artículo científico publicado en 2015

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

scientific article published on 21 January 2020

Targeting the protein kinase C family: are we there yet?

artículo científico publicado en 2007

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study ⬇️

artículo científico publicado en 2016

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis ⬇️

artículo científico publicado en 2013

Treatment for anthracycline-pretreated metastatic breast cancer

artículo científico publicado en 2002

Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model

artículo científico publicado en 2014

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

scientific article published on 12 March 2020

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

artículo científico publicado en 2008

Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo

artículo científico publicado el 1 de enero de 1992

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

artículo científico publicado en 1989

What is the effect of adjusting epirubicin doses for body surface area?

artículo científico publicado en 1998

Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?

artículo científico publicado en 2002

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

artículo científico publicado en 2004

Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda